"CONCLUSIONS
These data show that lumacaftor in combination with ivacaftor provided a benefit for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. (Funded by Vertex Pharmaceuticals and others; TRAFFIC and TRANSPORT ClinicalTrials.gov numbers,NCT01807923 and NCT01807949.)"
http://www.nejm.org/doi/full/10.1056/NEJMoa1409547?query=featured_home
No comments:
Post a Comment